CLINICAL PRACTICE OF BETA-BLOCKERS USAGE IN PATIENTS WITH CARDIOVASCULAR AND CHRONIC RESPIRATORY DISEASES. DATA OF OUTPATIENT REGISTRIES PROFILE AND RECVASA

Aim. To assess the practice of using beta-adrenoblockers (β-AB) in patients with cardiovascular diseases (CVD) in the presence of limitations (chronic obstructive pulmonary disease - COPD) and contraindications (bronchial asthma - BA) in two outpatient registries PROFILE and RECVASA.Material and met...

Full description

Saved in:
Bibliographic Details
Main Authors: S. Yu. Martsevich (Author), N. A. Zakharova (Author), N. P. Kutishenko (Author), A. V. Zagrebelnyy (Author), Yu. V. Lukina (Author), M. M. Loukianov (Author), A. N. Vorobyev (Author), A. N. Kozminsky (Author)
Format: Book
Published: Столичная издательская компания, 2017-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_db004c3bc9c84fc7b37a3ac6cc6b5b0a
042 |a dc 
100 1 0 |a S. Yu. Martsevich  |e author 
700 1 0 |a N. A. Zakharova  |e author 
700 1 0 |a N. P. Kutishenko  |e author 
700 1 0 |a A. V. Zagrebelnyy  |e author 
700 1 0 |a Yu. V. Lukina  |e author 
700 1 0 |a M. M. Loukianov  |e author 
700 1 0 |a A. N. Vorobyev  |e author 
700 1 0 |a A. N. Kozminsky  |e author 
245 0 0 |a CLINICAL PRACTICE OF BETA-BLOCKERS USAGE IN PATIENTS WITH CARDIOVASCULAR AND CHRONIC RESPIRATORY DISEASES. DATA OF OUTPATIENT REGISTRIES PROFILE AND RECVASA 
260 |b Столичная издательская компания,   |c 2017-09-01T00:00:00Z. 
500 |a 1819-6446 
500 |a 2225-3653 
500 |a 10.20996/1819-6446-2017-13-4-469-475 
520 |a Aim. To assess the practice of using beta-adrenoblockers (β-AB) in patients with cardiovascular diseases (CVD) in the presence of limitations (chronic obstructive pulmonary disease - COPD) and contraindications (bronchial asthma - BA) in two outpatient registries PROFILE and RECVASA.Material and methods. The data of the PROFILE registry organized in the specialized cardiological unit of the medical research center in Moscow from 2011 to 2015 (n=1531) were analyzed as well as data of the RECVASA registry included patients who applied to 3 city outpatient clinics in Ryazan from 2012 to 2013 (n=3690).Results. In the RECVASA registry 279 patients had COPD (mean age 73 years; 59.4% males); in the PROFILE registry 286 patients had COPD (mean age 66 years; 50.2% males). In the presence of COPD in the PROFILE registry, β-AB were prescribed more often (51.1%) than in the RECVASA registry (31.5%, p<0.01), primarily to patients with high cardiovascular risk [after myocardial infarction (MI) and in patients with chronic heart failure (CHF)]. In the PROFILE registry 28 patients had BA (mean age 67 years; 46.4% males); in the RECVASA registry - 188 patients (mean age 64 years; 16.5% males). In patients with BA the frequency of β-AB prescription decreased in both registries: 28.6% in the PROFILE registry and 19.1% in the RECVASA registry (p<0.01). In the PROFILE registry the presence of COPD did not influence β-AB administration is patients with ischemic heart disease and MI history; in the RECVASA registry in the presence of COPD the probability of β-AB administration decreased in patients with ischemic heart disease, MI and CHF. In the presence of BA the probability of β-AB administration decreased in both registries in all patients except hypertensive ones.Conclusion. Physicians of a specialized institution are more active than physicians of outpatient clinics in prescribing β-AB in COPD when direct indications to β-AB are present (previous MI, CHF) except uncomplicated hypertension. In patients with CVD and BA, doctors in both registries try not to prescribe β-AB. However, in uncomplicated hypertension, BA was often not taken into account, while prescribing β-AB. 
546 |a EN 
546 |a RU 
690 |a beta-adrenoblockers 
690 |a contraindications 
690 |a chronic obstructive pulmonary disease 
690 |a bronchial asthma 
690 |a registries 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Diseases of the circulatory (Cardiovascular) system 
690 |a RC666-701 
655 7 |a article  |2 local 
786 0 |n Рациональная фармакотерапия в кардиологии, Vol 13, Iss 4, Pp 469-475 (2017) 
787 0 |n https://www.rpcardio.online/jour/article/view/1506 
787 0 |n https://doaj.org/toc/1819-6446 
787 0 |n https://doaj.org/toc/2225-3653 
856 4 1 |u https://doaj.org/article/db004c3bc9c84fc7b37a3ac6cc6b5b0a  |z Connect to this object online.